학술논문

Urokinase-type Plasminogen Activator Receptor (uPAR) Ligation Induces a Raft-localized Integrin Signaling Switch That Mediates the Hypermotile Phenotype of Fibrotic Fibroblasts*
Document Type
article
Source
Journal of Biological Chemistry. 289(18)
Subject
Biochemistry and Cell Biology
Biological Sciences
Rare Diseases
Lung
Autoimmune Disease
2.1 Biological and endogenous factors
Aetiology
Respiratory
Animals
Blotting
Western
Caveolins
Cell Movement
Cells
Cultured
Fibroblasts
Fibronectins
Humans
Idiopathic Pulmonary Fibrosis
Integrin alpha5beta1
Membrane Microdomains
Mice
Microscopy
Fluorescence
Protein Binding
Proto-Oncogene Proteins c-fyn
RNA Interference
Receptors
Urokinase Plasminogen Activator
Severity of Illness Index
Shc Signaling Adaptor Proteins
Signal Transduction
Urokinase-Type Plasminogen Activator
Fibroblast
Fibrosis
Integrin
Lipid Raft
Urokinase Receptor
Chemical Sciences
Medical and Health Sciences
Biochemistry & Molecular Biology
Biological sciences
Biomedical and clinical sciences
Chemical sciences
Language
Abstract
The urokinase-type plasminogen activator receptor (uPAR) is a glycosylphosphatidylinositol-linked membrane protein with no cytosolic domain that localizes to lipid raft microdomains. Our laboratory and others have documented that lung fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) exhibit a hypermotile phenotype. This study was undertaken to elucidate the molecular mechanism whereby uPAR ligation with its cognate ligand, urokinase, induces a motile phenotype in human lung fibroblasts. We found that uPAR ligation with the urokinase receptor binding domain (amino-terminal fragment) leads to enhanced migration of fibroblasts on fibronectin in a protease-independent, lipid raft-dependent manner. Ligation of uPAR with the amino-terminal fragment recruited α5β1 integrin and the acylated form of the Src family kinase, Fyn, to lipid rafts. The biological consequences of this translocation were an increase in fibroblast motility and a switch of the integrin-initiated signal pathway for migration away from the lipid raft-independent focal adhesion kinase pathway and toward a lipid raft-dependent caveolin-Fyn-Shc pathway. Furthermore, an integrin homologous peptide as well as an antibody that competes with β1 for uPAR binding have the ability to block this effect. In addition, its relative insensitivity to cholesterol depletion suggests that the interactions of α5β1 integrin and uPAR drive the translocation of α5β1 integrin-acylated Fyn signaling complexes into lipid rafts upon uPAR ligation through protein-protein interactions. This signal switch is a novel pathway leading to the hypermotile phenotype of IPF patient-derived fibroblasts, seen with uPAR ligation. This uPAR dependent, fibrotic matrix-selective, and profibrotic fibroblast phenotype may be amenable to targeted therapeutics designed to ameliorate IPF.